Using Sugars to Target Triple-Negative Breast Tumors

Article

Researchers at the University of Illinois and collaborators in China have found a way to tag and target elusive cancers with small-molecule sugars by hijacking a cancer cell’s own metabolism.

Researchers at the University of Illinois and collaborators in China have found a way to tag and target elusive cancers with small-molecule sugars by hijacking a cancer cell’s own metabolism. This could open treatment pathways for cancers that are not responsive to conventional targeted antibodies, such as triple-negative breast cancer.

Publishing in the journal Nature Chemical Biology, the team reports that metabolic glycoengineering of unnatural sugars as a new tool to combat triple-negative breast cancer and potentially other malignancies. Targeted cancer therapies rely on specific markers on the surface of cancer cells. Scientists can design antibodies that seek out those markers and deliver therapeutic or imaging agents. However, some cancers are not eligible for targeted cancer therapies because they lack surface markers to target. 

“For example, we would like to target triple-negative breast cancer. This is a deadly breast cancer, with low survival rates,” said study investigator Jianjun Cheng, PhD, who is a professor of Materials Science and Engineering at the University of Illinois, Champaign, Ill. “We don’t have any targeted therapeutics so far, because it doesn’t have any of the receptors on it that we normally target. Our question was, can we create an artificial receptor?”

Cheng and colleagues found a way to mark the cells using azides, a class of small-molecule sugars. Once metabolized in the cell, they are expressed on the surface, and can be targeted by a molecule called dibenzocyclooctyl (DBCO). In some ways, it is like putting a key in a lock. Cheng said DBCO and azide react with each other with high specificity. Until now, the question has been, how do you put azide just on the tumor?

To make sure the azide would only be expressed on the surface of cancer cells, the researchers added a protective group to the azide sugar that could only be removed by tumor-specific enzymes. In normal tissues, the azide sugar simply travels through. In tumor cells, it is completely metabolized and expressed on the cell surface, creating specific targets for DBCO to deliver a cargo of cancer-treating drugs or imaging agents.

The researchers tested the azide-based targeting system in mice with tumors from colon cancer, triple-negative breast cancer, and metastatic breast cancer. The researchers found the tumors had very strong signals compared with other tissues.

 

  

 

 

 

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content